XM does not provide services to residents of the United States of America.
F
F

FreseniusMedical

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an
A
B
F
J
R
R
S
P
F

'Medicine is starting to work', JPM upgrades Fresenius

BUZZ-'Medicine is starting to work', JPM upgrades Fresenius ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an end ** The broker says Fresenius delivered results above expectations in each of the last four quarters and management made progress in improv
F
F

Banco, Shell, WH Smith

EUROPE RESEARCH ROUNDUP-Banco, Shell, WH Smith Sept 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Banco, Shell and WH Smith on Thursday. HIGHLIGHTS * ABN Amro Bank NV ABNd.AS : JP Morgan raises to neutral from underweight * Banco Bpm BAMI.MI : JP Morgan raises to neutral from underweight * Shell Plc SHEL.L : Berenberg cuts target price to 3,100p from 3,400p * UMG UMG.AS : Citigroup cuts target price to EUR 26 from EUR 29.50 *
A
B
B
B
C
C
C
C
D
D
D
D
E
E
E
E
I
I
I
N
O
P
R
R
R
S
S
W
P
A
B
B
F
L
U

Nestle replaces CEO Schneider with company veteran Freixe

UPDATE 6-Nestle replaces CEO Schneider with company veteran Freixe Adds Freixe's age and background in paragraph 15, and further comment, no other changes By John Revill and Richa Naidu ZURICH/LONDON, Aug 22 (Reuters) - Nestle NESN.S is replacing CEO Mark Schneider with company veteran Laurent Freixe, the Swiss food group said on Thursday, marking a change of leadership as it faces a challenge to grow sales.
D
N
F

Bodycote, Croda, Spectris

EUROPE RESEARCH ROUNDUP- Bodycote, Croda, Spectris July 31 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bodycote, Croda and Spectris, on Wednesday. HIGHLIGHTS * Bodycote Plc BOY.L : HSBC cuts target price to 940p from 950p * Bucher Industries AG BUCN.S : Berenberg cuts target price to CHF 464 from CHF 470 * Croda CRDA.L : HSBC cuts target price to 4400p from 4800p * Spectris Plc SXS.L : JP Morgan raises target price to 2,950p fr
A
A
A
B
B
B
C
C
C
C
D
D
E
E
G
G
H
I
L
S
S
S
A
D
F
I
I
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.